HCM
ENTA icon

Highbridge Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Highbridge Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,078
Closed -$215K – 1335
2016
Q3 		$215K Buy
+8,078
New +$188K ﹤0.01% 1155

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Highbridge Capital Management's ENTA Position: Q4 2016 in Review

Highbridge Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2016, closing a stake of 8,078 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in ENTA in Q3 2016 and held it in 1 quarter. The position peaked at $215K in Q3 2016. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

  • Highbridge Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 8,078 Enanta Pharmaceuticals shares in Q4 2016, an estimated $215K.
  • Highbridge Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Enanta Pharmaceuticals position peaked at $215K in Q3 2016.
  • 149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.